NCT00626197 - A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) | Biotech Hunter

Enrollment

381

Participants

Timeline

Start Date

February 15, 2008

Primary Completion Date

October 19, 2009

Study Completion Date

October 28, 2013

Conditions

Lupus NephritisSystemic Lupus Erythematosus

Interventions

DRUG

Corticosteroids

Intravenous and oral repeating dose

DRUG

Cyclophosphamide

Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.

DRUG

Mycophenolate Mofetil

Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.

DRUG

Ocrelizumab

Ocrelizumab was administed at a dose and as per schedule in arm description

DRUG

Placebo

Placebo was administered as per schedule in arm description

DRUG

Azathioprine

Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.